These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 37662491)

  • 21. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
    Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
    Front Immunol; 2020; 11():563044. PubMed ID: 33250890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.
    Hosseinkhani N; Derakhshani A; Shadbad MA; Argentiero A; Racanelli V; Kazemi T; Mokhtarzadeh A; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():676181. PubMed ID: 34093577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting novel inhibitory receptors in cancer immunotherapy.
    Ding QQ; Chauvin JM; Zarour HM
    Semin Immunol; 2020 Jun; 49():101436. PubMed ID: 33288379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma.
    Luo Y; Yang YC; Shen CK; Ma B; Xu WB; Wang QF; Zhang Y; Liao T; Wei WJ; Wang Y
    Front Endocrinol (Lausanne); 2022; 13():859013. PubMed ID: 35574031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
    Kreidieh FY; Tawbi HA
    Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
    Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
    Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
    Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
    Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy.
    Chiang EY; Mellman I
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors.
    Catalano M; Shabani S; Venturini J; Ottanelli C; Voltolini L; Roviello G
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NK Cell-Based Immune Checkpoint Inhibition.
    Khan M; Arooj S; Wang H
    Front Immunol; 2020; 11():167. PubMed ID: 32117298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer.
    Kitsou M; Ayiomamitis GD; Zaravinos A
    Int J Oncol; 2020 Jul; 57(1):237-248. PubMed ID: 32468013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer.
    Buckle I; Guillerey C
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
    Rotte A; Jin JY; Lemaire V
    Ann Oncol; 2018 Jan; 29(1):71-83. PubMed ID: 29069302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TIGIT/CD226 Axis Regulates Anti-Tumor Immunity.
    Yeo J; Ko M; Lee DH; Park Y; Jin HS
    Pharmaceuticals (Basel); 2021 Feb; 14(3):. PubMed ID: 33670993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune checkpoint markers and anti-CD20-mediated NK cell activation.
    Wang Z; Weiner GJ
    J Leukoc Biol; 2021 Oct; 110(4):723-733. PubMed ID: 33615552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TIGIT axis: novel immune checkpoints in anti-leukemia immunity.
    Qiu D; Liu X; Wang W; Jiang X; Wu X; Zheng J; Zhou K; Kong X; Wu X; Jin Z
    Clin Exp Med; 2023 Jun; 23(2):165-174. PubMed ID: 35419661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
    Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
    Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance to Checkpoint Inhibition in Cancer Immunotherapy.
    Barrueto L; Caminero F; Cash L; Makris C; Lamichhane P; Deshmukh RR
    Transl Oncol; 2020 Mar; 13(3):100738. PubMed ID: 32114384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
    Kok VC
    Front Oncol; 2020; 10():268. PubMed ID: 32185135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.